ISSN 1671-5411 CN 11-5329/R
Volume 17 Issue 8
Sep.  2020
Turn off MathJax
Article Contents
Xiao-Si JIANG, Li-Chao TIAN, Zi-Chao JIANG, Yu-Ting ZOU, Ping LI, Xin-Chun YANG, Xi SU, Jin-Wen TIAN, Bei SHI, Zong-Zhuang LI, Yong-Jun LI, Ren-Qiang YANG, Geng QIAN, Yun-Dai CHEN. Effects of nicorandil on myocardial infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: study design and protocol for the randomized controlled trial. J Geriatr Cardiol 2020; 17(8): 519-524. doi: 10.11909/j.issn.1671-5411.2020.08.002
Citation: Xiao-Si JIANG, Li-Chao TIAN, Zi-Chao JIANG, Yu-Ting ZOU, Ping LI, Xin-Chun YANG, Xi SU, Jin-Wen TIAN, Bei SHI, Zong-Zhuang LI, Yong-Jun LI, Ren-Qiang YANG, Geng QIAN, Yun-Dai CHEN. Effects of nicorandil on myocardial infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: study design and protocol for the randomized controlled trial. J Geriatr Cardiol 2020; 17(8): 519-524. doi: 10.11909/j.issn.1671-5411.2020.08.002

Effects of nicorandil on myocardial infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: study design and protocol for the randomized controlled trial

doi: 10.11909/j.issn.1671-5411.2020.08.002
More Information
  • Corresponding author: Geng QIAN, Department of Cardiology, the First Medical Center of Chinese PLA General Hospital, Beijing, China. E-mail: qiangeng 9396@263.net; Yun-Dai CHEN, Department of Cardiology, the First Medical Center of Chinese PLA General Hospital, Beijing, China. E-mails: cyundai@vip.163.com
  • Received Date: 2020-06-03
  • Accepted Date: 2020-07-25
  • Rev Recd Date: 2020-07-10
  • Available Online: 2020-08-28
  • Publish Date: 2020-09-07
  • Previous studies have shown that nicorandil has a protective effect on cardiomyocytes. However, there is no study to investigate whether perioperative intravenous nicorandil can further reduce the myocardial infarct size in patients with ST-segment elevation myocardial infarction (STEMI) compared to the current standard of percutaneous coronary intervention (PCI) regimen. The CHANGE (China-Admini stration of Nicorandil Group) study is a multicenter, prospective, randomized, double-blind and parallel-controlled clinical study of STEMI patients undergoing primary PCI in China, aiming to evaluate the efficacy and safety of intravenous nicorandil in ameliorating the myocar dial infarct size in STEMI patients undergoing primary PCI and provide evidence-based support for myocardial protection strategies of STEMI patients.
  • loading
  • [1]
    Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014; 129: 1493- 1501. doi: 10.1161/CIRCULATIONAHA.113.004046
    [2]
    Ma LY, Chen WW, Gao RL, et al. China cardiovascular diseases report 2018: an updated summary. J Geriatr Cardiol 2020; 17: 1-8.
    [3]
    World Health Organization. About cardiovascular diseases (CVDs). World Health Organization of cardiovascular dis eases Web site. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed August 8, 2020).
    [4]
    The World Bank. Toward a healthy and harmonious life in China: stemming the rising tide of non-communicable dis eases, 2011. The World Bank Web site. https://www.worldbank.org/content/dam/Worldbank/document/NCD_report_en.pdf#:~:text=Toward%20a%20Healthy%20and%20Harmonious%20Life%20in%20China%3A,the%20response%20over%20the%20medium%20and%20longer%20terms (accessed Aug 8, 2020).
    [5]
    Kaul P, Ezekowitz JA, Armstrong PW, et al. Incidence of heart failure and mortality after acute coronary syndromes. Am Heart J 2013; 165: 379-385. doi: 10.1016/j.ahj.2012.12.005
    [6]
    Niccoli G, Cosentino N, Spaziani C, et al. No-reflow: in ci dence and detection in the cath-lab. Curr Pharm Des 2013; 19: 4564-4575. doi: 10.2174/1381612811319250005
    [7]
    Salinas P, Jimenez-Valero S, Moreno R, et al. Update in phar macological management of coronary no-reflow phenomenon. Cardiovasc Hematol Agents Med Chem 2012; 10: 256-264. doi: 10.2174/187152512802651024
    [8]
    Jahangir A, Terzic A. K(ATP) channel therapeutics at the bedside. J Mol Cell Cardiol 2005; 39: 99-112. doi: 10.1016/j.yjmcc.2005.04.006
    [9]
    Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischae mia in patients: preconditioning and postconditioning. Cardio vasc Res 2009; 83: 234-246. doi: 10.1093/cvr/cvp129
    [10]
    Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a precon ditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000; 35: 345-351. doi: 10.1016/S0735-1097(99)00539-2
    [11]
    Lader JM, Vasquez C, Bao L, et al. Remodeling of atrial ATP-sensitive K+ channels in a model of salt-induced elevated blood pressure. Am J Physiol Heart Circ Physiol 2011; 301: H964-H974. doi: 10.1152/ajpheart.00410.2011
    [12]
    Nazir SA, McCann GP, Greenwood JP, et al. Strategies to attenuate micro-vascular obstruction during P-PCI: the rando mized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. Eur Heart J 2016; 37: 1910-1919. doi: 10.1093/eurheartj/ehw136
    [13]
    Jogiya R, Kozerke S, Morton G, et al. Validation of dynamic 3-dimensional whole heart magnetic resonance myocardial perfusion imaging against fractional flow reserve for the detection of significant coronary artery disease. J Am Coll Cardiol 2012; 60: 756-765. doi: 10.1016/j.jacc.2012.02.075
    [14]
    Hamirani YS, Wong A, Kramer CM, et al. Effect of micro vascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial in farc tion: a systematic review and meta-analysis. JACC Cardio vasc Imaging 2014; 7: 940-952. doi: 10.1016/j.jcmg.2014.06.012
    [15]
    Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660. doi: 10.1016/S0735-1097(98)00604-4
    [16]
    Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-1288. doi: 10.1161/CIRCULATIONAHA.104.530329
    [17]
    Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-1493. doi: 10.1016/S0140-6736(07)61634-1
    [18]
    Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nico randil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potas sium channels. J Cardiovasc Pharmacol 1995; 26: 541-547. doi: 10.1097/00005344-199510000-00006
    [19]
    Kin H, Zhao ZQ, Sun HY, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004; 62: 74-85. doi: 10.1016/j.cardiores.2004.01.006
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Article Metrics

    Article views (207) PDF downloads(9) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return